Table 2 Patient characteristics in randomized trials of beta blockers for the prevention of sudden cardiac death

Anderson et al.

50

66

IDC

Non-ischaemic

29

II-IV

ANZ¹³

67

80

chronic heart failure

Ischaemic

29

II-III

BEST⁶

60

78

NYHA III-IV, EF ≤ 35%

Both

23

III-IV

BHAT³⁹

55

NR

MI, HF

NR

NR

NR

Bristow et al.¹⁴

55

61

IDC and ISCD

Both

24

I-IV

Bristow et al.¹⁵

60

76

Mild, moderate, chronic heart failure

Both

23

II-IV

CAPRICORN¹⁶

63

74

Acute MI, EF ≤ 40%

Ischaemic

32

NR

CELICARD³³

57

89.5

NYHA II- IV, LVEF<40%

Both

26

II-III

CIBIS II¹⁸

61

80

NYHA III or IV, EF ≤ 35%

Both

28

III-IV

CIBIS¹⁷

60

83

IDC, NYHA III-IV, ≤ 40%

Both

25

III-IV

Colucci et al.¹⁹

54

85

Mildly symptomatic heart failure

Both

23

II-III

COPERNICUS²⁰

63.3

79.5

HF and EF ≤ 25%

67% ischaemic

20

NR

De Milliano et al.³⁴

65

60

HF,, LVEF<35%,

Both

25

II-III

ELANDD³⁵

66

35

HF, age>40 years, LVEF>45%

Non-ischaemic

62

II-III

Engleimeir et al.²¹

50

64

IDC

Both

17

II-III

Fisher et al²²

63

96

HF and CAD

NR

23

II-IV

Hansteen V. et al.²³

58

84.5

Acute MI

NR

NR

NR

Krum et al.²⁴

55

78

Advanced heart failure

Both

16

II-IV

MDC²⁵

49

73

DCM and EF<40%

Non-ischaemic

22

I-III

MERIT-HF²⁶

64

77

NYHA II-IV,EF ≤ 40%

Both

28

II-IV

Metra et al.²⁷

51

90

NYHA II-III, IDC

Non-ischaemic

20

II-III

Olsen et al.²⁸

52

94

NYHA II-III, IDC/CAD

Both

20

II-IV

Packer et al.²⁹

58

77

Chronic heart failure

Both

23

II-IV

Pollock et al.³⁰

54

79

CHF

Both

21

II-IV

RESOLVD³⁶

62

82

CHF(NYHA II- IV), LVEF<35%

Both

28.5

I-IV

SENIORS¹¹

76

63

HF,EF ≤ 35%

NR

35

I-IV

Sturm et al.³⁷

62

88

Age(18-75), LVEF≤25%

Both

17

II-IV

UHLIR et al.³⁸

56

89

Age(18-75), NYHA II- III, LVEF<40%

Ischaemic

NR

II-III

Wisenbaugh et al.¹²

50

50

NYHA II-III, IDC/ISCD

Both

24

II-III

Woodley et al.¹⁰

52

72

NYHA II- III, IDC/CAD

Both

22

II-III